{
    "id": 3554,
    "fullName": "NRAS G13D",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "NRAS G13D is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). G13D confers a loss of function on Nras protein as indicated by increased GTP-bound Nras, which leads to activation of downstream pathway signaling in cell culture (PMID: 17517660).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2101,
                    "pubMedId": 17517660,
                    "title": "NRAS mutation causes a human autoimmune lymphoproliferative syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17517660"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4893,
        "geneSymbol": "NRAS",
        "terms": [
            "NRAS",
            "ALPS4",
            "CMNS",
            "N-ras",
            "NCMS",
            "NRAS1",
            "NS6"
        ]
    },
    "variant": "G13D",
    "createDate": "03/05/2015",
    "updateDate": "09/20/2018",
    "referenceTranscriptCoordinates": {
        "id": 162442,
        "transcript": "NM_002524",
        "gDna": "chr1:g.114716123C>T",
        "cDna": "c.38G>A",
        "protein": "p.G13D",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6602,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring NRAS G13D in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 3361,
                "profileName": "NRAS G13D"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6593,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS G13D in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 3361,
                "profileName": "NRAS G13D"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6610,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cells harboring NRAS G13D were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 3361,
                "profileName": "NRAS G13D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10843,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13D in culture (PMID: 28235199).",
            "molecularProfile": {
                "id": 3361,
                "profileName": "NRAS G13D"
            },
            "therapy": {
                "id": 5658,
                "therapyName": "3144",
                "synonyms": null
            },
            "indication": {
                "id": 50523,
                "name": "adult T-cell leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8866,
                    "pubMedId": 28235199,
                    "title": "Multivalent Small-Molecule Pan-RAS Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28235199"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3361,
            "profileName": "NRAS G13D",
            "profileTreatmentApproaches": [
                {
                    "id": 16453,
                    "name": "MEK2 Inhibitor",
                    "profileName": "NRAS G13D"
                },
                {
                    "id": 16455,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "NRAS G13D"
                },
                {
                    "id": 16452,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "NRAS G13D"
                },
                {
                    "id": 16454,
                    "name": "PIK3CA inhibitor",
                    "profileName": "NRAS G13D"
                },
                {
                    "id": 16456,
                    "name": "MEK1 Inhibitor",
                    "profileName": "NRAS G13D"
                },
                {
                    "id": 16451,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "NRAS G13D"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 162442,
            "transcript": "NM_002524",
            "gDna": "chr1:g.114716123C>T",
            "cDna": "c.38G>A",
            "protein": "p.G13D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}